 |
|
|
|
|
|
|
|
|
|
| |
 |
Documents of Interest
|
|
|
| |
|
Archived Documents |
|
| |
|
|
|
|
Documents of Interest |
|
|
| |
|
Workshops, Safety Symposia, and Safety and Policy Conferences |
|
|
| |
|
Biosafety Considerations for Research with Lentiviral Vectors |
|
|
| |
|
Conclusions and Recommendations of the RAC Gene Transfer Safety Symposium: Current Perspectives on Gene Transfer for X-SCID
(March 15, 2005) |
|
|
| |
|
Letter to Principal Investigators Conveying RAC Recommendations Regarding Adverse Events in a Gene Transfer Trial Studying X-linked SCID
(March 20, 2003) |
|
|
| |
|
Assessment of Adenoviral Vector Safety and Toxicity: Report of the National Institutes of Health Recombinant DNA Advisory Committee |
|
|
| |
|
Report from the ACD Working Group - Enhancing the Protection of Human Subjects in Gene Transfer Research at the National Institutes of Health
(July 12, 2000) |
|
|
| |
|
Statement by Dr. Amy Patterson to the Subcommittee on Public Health, U.S. Senate
(February 2, 2000) |
|
|
| |
|
Letter from OBA--Requirements for Reporting Serious Adverse Events: Request for Institutional Review
(November 22, 1999) |
|
|
| |
|
FDA Letter to IND Sponsors/Principal Investigators of Gene Transfer Clinical Trials Regarding Protocol Submission and Adverse Event Requirements
(November 5, 1999) |
|
|
| |
|
RAC Statement Regarding In Utero Gene Transfer Research
(March 11, 1999) |
|
|
| |
|
Environmental Assessment and Finding of No Significant Impact
(approved by the NIH Director on October 22, 1997) |
|
|
| |
|
Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy (Orkin/Motulsky Report)
(December 7, 1995) |
|
|
| |
|
Ad Hoc Review Committee - Executive Summary of Findings and Recommendations (Verma Report)
(September 8, 1995) |
|
Top of Page |